What is disease mongering?
Disease mongering is the widening of the boundaries of illness, or the promotion of new diagnoses, in ways that expand the market for medical treatment beyond where the evidence clearly supports it. In plain terms, it is the process by which ordinary experiences, normal differences between people, and simple risk factors get relabeled as conditions that require diagnosis and, usually, a product to treat them. The phrase is a criticism of where a medical line is drawn, not a claim that real diseases do not exist.
This page is part of an independent literacy reference. It has no connection to the 2006 conference that popularized the term or to any prior owner of the domain, and it offers no medical advice. It explains how a label works and how the debate around it runs; it never tells any individual reader whether a condition applies to them.
The meaning of the term
The word “mongering” means dealing in or stirring up something, as in fearmongering or rumor-mongering. Applied to health, it describes stirring up demand for diagnoses and treatments. The writer Lynn Payer introduced the phrase in her 1992 book Disease-Mongers, and the journalists Ray Moynihan and Alan Cassels carried it into wide use with Selling Sickness in 2005. Because the compound is a technical English phrase, it is often left untranslated in other languages, and its meaning is best captured by the underlying idea rather than by any single dictionary entry: sickness can be marketed like any other commodity when the definition of who counts as sick is flexible enough.
What disease mongering is not
Clarity about the concept requires saying plainly what it does not mean. It does not mean that cancer, diabetes, heart disease, or mental illness are inventions. It does not mean that any particular person’s diagnosis is false, and it is not a reason to stop a prescribed treatment. It is not a conspiracy theory about a secret cabal. The critique is narrower and more careful than any of those. It concerns the margins of medicine, the zone where an extra diagnosis brings little benefit, where the harms of labeling and medicating are underplayed, and where the parties deciding the threshold have a financial stake in the answer.
How a condition gets expanded
Disease mongering usually operates through a small number of repeatable moves rather than one dramatic act. Recognizing them is the core skill this reference tries to build.
- Lowering the threshold. A committee redraws a cutoff for blood pressure, blood sugar, or bone density, and millions who were “normal” become patients overnight.
- Treating risk as disease. A number that merely predicts a future problem is given a disease-sounding name, so the risk factor itself becomes the diagnosis.
- Naming and branding. A loose set of complaints receives a crisp clinical name and an acronym, which makes it feel like a settled entity.
- Manufacturing awareness. Campaigns, sometimes funded by the maker of the relevant product, teach the public to read an everyday feeling as a symptom and to ask a clinician about it.
These are examined step by step on the page about the tactics of disease mongering, which treats them as a coherent playbook rather than isolated tricks.
Disease versus illness
The concept leans on a distinction that everyday speech blurs. A disease is a defined biological abnormality, often fixed by an agreed cutoff. An illness is the felt experience of being unwell. The two can come apart: a person may carry a disease label yet feel fine, or feel genuinely unwell while meeting no diagnostic threshold. Disease mongering works in the space between them, either attaching a disease name to an ordinary discomfort or turning a laboratory reading into a condition that a person is then told to worry about and manage.
Examples that recur in the debate
The same cases appear repeatedly because each shows a real spectrum whose treatable portion was stretched. Low testosterone, or “Low T,” reframed ordinary aging in men as a hormone deficiency. Social anxiety disorder was marketed alongside antidepressants in a way that risked folding common shyness into a chronic diagnosis. Prehypertension and prediabetes gave disease-like names to below-threshold cardiovascular and metabolic numbers. Osteopenia turned below-average bone density into a treatment target, and restless legs syndrome, a real sensation, was promoted as a far more widespread disorder than the evidence supported. Each underlying condition can be real for some people; the criticism concerns the size of the group told they need lifelong treatment. The examples page walks through a fuller set fairly.
Why it matters
The stakes are practical. Every diagnosis carries costs as well as benefits: the anxiety of being told one is sick, the side effects and expense of treatment, and the diversion of attention and resources from people with more serious disease. At the same time, medicalization has done real good, legitimizing suffering that was once dismissed and opening access to care, so the answer is rarely to reject a label wholesale. The value of understanding disease mongering is that it lets a reader ask better questions: Who widened this definition? What is the evidence that treating the mild end helps? Who profits if more people are diagnosed? Those questions, applied case by case, are what separate medicine that finds disease from marketing that manufactures it. The pillar overview, Disease mongering: turning ordinary life into treatable illness, sets out the whole picture and routes to the deeper material.